A detailed history of Crossmark Global Holdings, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 37,103 shares of LLY stock, worth $32.6 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
37,103
Previous 36,510 1.62%
Holding current value
$32.6 Million
Previous $28.4 Million 18.27%
% of portfolio
0.64%
Previous 0.54%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$724.87 - $909.04 $429,847 - $539,060
593 Added 1.62%
37,103 $33.6 Million
Q1 2024

May 13, 2024

SELL
$592.2 - $792.28 $362,426 - $484,875
-612 Reduced 1.65%
36,510 $28.4 Million
Q4 2023

Feb 13, 2024

SELL
$525.19 - $619.13 $841,354 - $991,846
-1,602 Reduced 4.14%
37,122 $21.6 Million
Q3 2023

Nov 08, 2023

SELL
$434.7 - $599.3 $160,839 - $221,740
-370 Reduced 0.95%
38,724 $22.4 Million
Q2 2023

Jul 31, 2023

BUY
$350.74 - $468.98 $210,794 - $281,856
601 Added 1.56%
39,094 $17.9 Million
Q1 2023

May 12, 2023

SELL
$310.63 - $364.82 $4.92 Million - $5.78 Million
-15,839 Reduced 29.15%
38,493 $13.2 Million
Q4 2022

Jan 19, 2023

SELL
$321.55 - $374.67 $2.13 Million - $2.48 Million
-6,620 Reduced 10.86%
54,332 $19.9 Million
Q3 2022

Nov 01, 2022

SELL
$296.48 - $337.87 $217,912 - $248,334
-735 Reduced 1.19%
60,952 $19.7 Million
Q2 2022

Jul 29, 2022

BUY
$278.73 - $327.27 $848,732 - $996,537
3,045 Added 5.19%
61,687 $20 Million
Q1 2022

May 11, 2022

SELL
$234.69 - $291.66 $60,784 - $75,539
-259 Reduced 0.44%
58,642 $16.8 Million
Q4 2021

Jan 10, 2022

SELL
$224.85 - $279.04 $19.6 Million - $24.3 Million
-87,108 Reduced 59.66%
58,901 $16.3 Million
Q3 2021

Oct 21, 2021

BUY
$221.6 - $272.71 $27.3 Million - $33.6 Million
123,128 Added 538.12%
146,009 $33.7 Million
Q3 2021

Oct 13, 2021

SELL
$221.6 - $272.71 $27.1 Million - $33.3 Million
-122,118 Reduced 84.22%
22,881 $1.09 Million
Q2 2021

Jul 21, 2021

BUY
$180.55 - $233.54 $71,317 - $92,248
395 Added 0.27%
144,999 $33.3 Million
Q1 2021

Apr 15, 2021

SELL
$164.32 - $212.72 $1.33 Million - $1.72 Million
-8,078 Reduced 5.29%
144,604 $27 Million
Q4 2020

Jan 14, 2021

BUY
$130.46 - $172.63 $9.77 Million - $12.9 Million
74,857 Added 96.19%
152,682 $25.8 Million
Q3 2020

Oct 08, 2020

SELL
$146.22 - $169.13 $42,403 - $49,047
-290 Reduced 0.37%
77,825 $11.5 Million
Q2 2020

Aug 14, 2020

BUY
$136.42 - $164.18 $214,452 - $258,090
1,572 Added 2.05%
78,115 $12.8 Million
Q1 2020

Apr 28, 2020

SELL
$119.05 - $147.35 $569,416 - $704,775
-4,783 Reduced 5.88%
76,543 $10.6 Million
Q4 2019

Feb 06, 2020

SELL
$106.92 - $132.43 $1.1 Million - $1.36 Million
-10,283 Reduced 11.22%
81,326 $10.7 Million
Q3 2019

Oct 09, 2019

SELL
$106.79 - $116.16 $314,069 - $341,626
-2,941 Reduced 3.11%
91,609 $10.2 Million
Q2 2019

Jul 09, 2019

SELL
$110.79 - $129.32 $881,777 - $1.03 Million
-7,959 Reduced 7.76%
94,550 $10.5 Million
Q1 2019

May 02, 2019

SELL
$111.31 - $131.02 $415,742 - $489,359
-3,735 Reduced 3.52%
102,509 $13.3 Million
Q4 2018

Jan 31, 2019

BUY
$105.9 - $118.64 $468,819 - $525,219
4,427 Added 4.35%
106,244 $12.3 Million
Q3 2018

Nov 08, 2018

SELL
$85.86 - $107.31 $362,500 - $453,062
-4,222 Reduced 3.98%
101,817 $10.9 Million
Q2 2018

Jul 31, 2018

SELL
$75.7 - $86.88 $355,638 - $408,162
-4,698 Reduced 4.24%
106,039 $9.05 Million
Q1 2018

Apr 16, 2018

SELL
$74.21 - $87.6 $41,409 - $48,880
-558 Reduced 0.5%
110,737 $8.57 Million
Q4 2017

Feb 05, 2018

BUY
$81.94 - $87.89 $664,697 - $712,963
8,112 Added 7.86%
111,295 $9.4 Million
Q3 2016

Oct 25, 2017

BUY
N/A
103,183
103,183 $8.83 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $834B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.